VolitionRx (VNRX) said Friday its automated Nu.Q Cancer immunoassay test in development detected 21 different types of cancer in a recent study.
The study included 229 cancer patients and 150 healthy participants and demonstrated that the test detected common fatal cancers, including lung, breast, prostate, colon and liver, with a very low rate of false positives, Volition RX said.
This technology could function as a standalone pan-cancer test or be licensed for use with other liquid biopsy tools, largely due to its low false positive rate in healthy individuals, the company said.
VolitionRX said it is in discussions with multiple major diagnostic and liquid biopsy firms to secure licensing deals this year that include milestone-based payments and ongoing revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.